Interferon alpha 2B/interleukin 2
1
Reactions 509 - 9 Jul 1994 Interferon alpha 2B/interleukin 2 S Rapid neurological decline in a patient with multiple sclerosis: case report A patient with multiple sclerosis [age and sex not stated] experienced rapid neurological decline after treatment with systemic interleukin 2 and interferon- α2B [dosages not stated] for metastatic renal cell carcinoma. The symptoms began after 3 days of commencing therapy with interleukin 2; therapy with both interleukin 2 and interferon-α2B was stopped on day 8. Normal visual acuity returned within 3 days, however, paraplegia and upper extremity dysfunction persisted. Author comment: This is ‘the first case of rapid neurologic decline in an MS [multiple sclerosis] patient treated with systemic IL-2 [interleukin 2] and INF-alpha 2b [interferon-α2B] . . . We propose that permanent worsening occurred due to in vivo stimulation of activated T cells and/or elaboration of cytotoxic lymphokines.’ Kinkel RP, et al. Rapid neurologic decline in an MS patient treated with systemic interleukin 2 (IL-2) and interferon alpha (INF-alpha 2b). Neurology 44 (Suppl. 2): 392, Apr 1994 800264377 1 Reactions 9 Jul 1994 No. 509 0114-9954/10/0509-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Interferon alpha 2B/interleukin 2
Reactions 509 - 9 Jul 1994
Interferon alpha 2B/interleukin 2
SRapid neurological decline in a patient with multiplesclerosis: case report
A patient with multiple sclerosis [age and sex notstated] experienced rapid neurological decline aftertreatment with systemic interleukin 2 and interferon-α2B [dosages not stated] for metastatic renal cellcarcinoma.
The symptoms began after 3 days of commencingtherapy with interleukin 2; therapy with both interleukin2 and interferon-α2B was stopped on day 8. Normalvisual acuity returned within 3 days, however,paraplegia and upper extremity dysfunction persisted.
Author comment: This is ‘the first case of rapidneurologic decline in an MS [multiple sclerosis] patienttreated with systemic IL-2 [interleukin 2] and INF-alpha2b [interferon-α2B] . . . We propose that permanentworsening occurred due to in vivo stimulation ofactivated T cells and/or elaboration of cytotoxiclymphokines.’Kinkel RP, et al. Rapid neurologic decline in an MS patient treated with systemicinterleukin 2 (IL-2) and interferon alpha (INF-alpha 2b). Neurology 44 (Suppl. 2):392, Apr 1994 800264377
1
Reactions 9 Jul 1994 No. 5090114-9954/10/0509-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
